Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 6/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 6/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 3/20 | 0.42 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.42 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.41 |
| ▸ | LAP3 | P28838 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7787361 | 0.86 | S1PR2 (0.44) | S1PR2S1PR1S1PR3S1PR4FFAR1 | |
| SCHEMBL9668817 | 0.85 | S1PR2 (0.44) | S1PR2S1PR1S1PR3S1PR4FFAR4 | |
| SCHEMBL2639555 | 0.84 | FFAR1 (0.46) | FFAR4FFAR1NFKB1GPR84 | |
| SCHEMBL7584644 | 0.84 | FFAR1 (0.46) | FFAR4FFAR1NFKB1GPR84 | |
| SCHEMBL7584671 | 0.83 | FFAR1 (0.45) | FFAR4FFAR1NFKB1GPR84 | |
| SCHEMBL2639401 | 0.82 | LPAR5 (0.52) | S1PR2S1PR1S1PR3LPAR3LPAR2 | |
| SCHEMBL9506889 | 0.82 | LPAR5 (0.52) | S1PR2S1PR1S1PR3LPAR3LPAR2 | |
| SCHEMBL7584666 | 0.81 | FFAR1 (0.49) | FFAR4FFAR1NFKB1GPR84 | |
| SCHEMBL2502773 | 0.81 | FFAR1 (0.43) | FFAR4FFAR1NFKB1GPR84 | |
| SCHEMBL25139921 | 0.80 | FFAR4 (0.51) | FFAR4FFAR1NFKB1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534213-B1 | WATER-BASED DELIVERY SYSTEMS | SKOELD THOMAS (SE) | 2013-04-24 | — | — | EP | claimed |
| JP-4806519-B2 | — | — | 2011-11-02 | — | — | JP | claimed |
| US-20090226491-A1 | Water-based delivery systems | SKOLD, THOMAS (SE) | 2009-09-10 | — | — | US | claimed |
| US-20090081139-A1 | Water-based delivery systems | GALDERMA LABORATORIES, INC. | 2009-03-26 | — | — | US | claimed |
| WO-2006039667-A2 | WATER-BASED DELIVERY SYSTEMS | COLLAGENEX PHARMACEUTICALS, INC. (US) | 2006-04-13 | — | — | WO | claimed |
| EP-1534213-A4 | WATER-BASED DELIVERY SYSTEMS | COLLAGENEX PHARM INC (US) | 2005-10-26 | — | — | EP | claimed |
| US-20050129722-A1 | For an active substance, characterized by enhancing skin barrier restoration in the stratum corneum comprising a fatty acid, cholesterol, a ceramide and at least one skin lipid precursor; topical drug delivery | COLLAGENEX PHARMACEUTICALS, INC. | 2005-06-16 | — | — | US | claimed |
| EP-1534213-A2 | WATER-BASED DELIVERY SYSTEMS | Collagenex Pharmaceuticals, Inc. (US) | 2005-06-01 | — | — | EP | claimed |
| US-20040009213-A1 | Water-based delivery systems | COLLAGENEX PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | claimed |
| WO-2003077861-A2 | WATER-BASED DELIVERY SYSTEMS | COLLAGENEX PHARMACEUTICALS, INC. (US) | 2003-09-25 | — | — | WO | claimed |
| EP-1534213-B1 | WATER-BASED DELIVERY SYSTEMS | SKOELD THOMAS (SE) | 2013-04-24 | — | — | EP | disclosed |
| US-8029810-B2 | Water-based delivery systems | Skold, Thomas (SE) | 2011-10-04 | — | — | US | disclosed |
| US-20090226491-A1 | Water-based delivery systems | SKOLD, THOMAS (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090081139-A1 | Water-based delivery systems | GALDERMA LABORATORIES, INC. | 2009-03-26 | — | — | US | disclosed |
| EP-1534213-A4 | WATER-BASED DELIVERY SYSTEMS | COLLAGENEX PHARM INC (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20050129722-A1 | For an active substance, characterized by enhancing skin barrier restoration in the stratum corneum comprising a fatty acid, cholesterol, a ceramide and at least one skin lipid precursor; topical drug delivery | COLLAGENEX PHARMACEUTICALS, INC. | 2005-06-16 | — | — | US | disclosed |
| EP-1534213-A2 | WATER-BASED DELIVERY SYSTEMS | Collagenex Pharmaceuticals, Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040009213-A1 | Water-based delivery systems | COLLAGENEX PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
| WO-2003077861-A2 | WATER-BASED DELIVERY SYSTEMS | COLLAGENEX PHARMACEUTICALS, INC. (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050129722-A1 | For an active substance, characterized by enhancing skin barrier restoration in the stratum corneum comprising a fatty acid, cholesterol, a ceramide and at least one skin lipid precursor; topical drug delivery | CERT1, CERS2, SGMS1 | S1PR2 43/4885S1PR1 33/4885S1PR3 40/4885 |
| US-20090226491-A1 | Water-based delivery systems | CERS2, SGMS2, SGMS1 | S1PR2 55/4885S1PR1 48/4885S1PR3 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.